Cerenome (CNSY) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
31 Mar, 2026Voting matters and shareholder proposals
Election of six directors for a one-year term, with nominees listed for shareholder approval.
Ratification of CBIZ P.C. as the independent registered public accounting firm for the 2026 fiscal year.
Advisory vote on executive compensation for named executive officers.
Approval of the Sixth Amendment and Restatement of the 2020 Stock Incentive Plan.
Additional business may be transacted as properly brought before the meeting.
Board of directors and corporate governance
Six director nominees are presented for election, each to serve until the 2027 annual meeting or until a successor is elected.
Executive compensation and say-on-pay
Shareholders are asked to provide a non-binding advisory vote on the compensation of named executive officers.
Proposal includes approval of amendments to the 2020 Stock Incentive Plan.
Latest events from Cerenome
- Q2 2026 marked rebranding, clinical progress, and a $9.0M net loss amid capital constraints.CNSY
Q2 2026 - Cerenome rebrands and advances CNS oncology with integrated therapeutics, diagnostics, and AI.CNSY
Investor update - Shelf registration allows flexible securities offerings; Canaccord Genuity LLC is distribution agent.CNSY
Registration filing - At-the-market equity offering of up to $17.35M targets CNS cancer innovation, with dilution risk.CNSY
Registration filing - 186RNL shows safety, efficacy, and immune activation in leptomeningeal metastases.CNSY
2026 AANS Annual Scientific Meeting presentation - Net loss narrowed, cash and investments rose, and funding remains critical amid clinical and commercial progress.CNSY
Q1 2026 - All proposals, including board election and stock plan amendment, were approved by shareholders.CNSY
AGM 2026 - $15M raise funds pivotal trials, CNSide scale-up, and 2026 commercial expansion.CNSY
Business update - $15M financing and clinical progress support CNSide's 2025 launch and CNS cancer milestones.CNSY
Q4 2024